Nanobiotix SA

Voting Rights and Shares Capital of the Company

12 فبراير 2025 15:15:00 بحسب Nasdaq GlobeNewswire

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

29 يناير 2025 15:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

21 يناير 2025 01:30:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

09 يناير 2025 15:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

17 ديسمبر 2024 15:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 ديسمبر 2024 15:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

09 ديسمبر 2024 15:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 نوفمبر 2024 15:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

12 نوفمبر 2024 01:30:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX to Participate in Multiple Investor Conferences in November

31 أكتوبر 2024 02:30:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 أكتوبر 2024 15:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

18 سبتمبر 2024 15:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

04 سبتمبر 2024 15:15:00 بحسب Nasdaq GlobeNewswire

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 سبتمبر 2024 15:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

08 أغسطس 2024 15:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

09 يوليو 2024 15:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

12 يونيو 2024 15:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 يونيو 2024 15:15:00 بحسب Nasdaq GlobeNewswire

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

02 يونيو 2024 09:00:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

28 مايو 2024 15:15:00 بحسب Nasdaq GlobeNewswire